Optimalna medikamentna terapija u bolesnika s reduciranom sistoličkom funkcijom by Rahimy, Mohammad Tareq
 UNIVERSITY OF ZAGREB 
SCHOOL OF MEDICINE 
 
 
Mohammad Tareq Rahimy 
 
 
 
OPTIMAL MEDICAL TREATMENT FOR 
HEART FAILURE WITH 
REDUCED EJECTION FRACTION 
 
 
GRADUATE THESIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zagreb, 2018 
  
“This graduate thesis was made at the department of Cardiology, mentored by Doc. 
Dr.sc. Bosko Skoric and was submitted for evaluation in the academic year of 
2017/2018”.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Abbreviations  
 
HF- Heart Failure 
EF- Ejection Fraction 
LV- Left ventricular  
HFrEF- Heart failure with reduced ejection fraction 
HFpEF- Heart failure with preserved ejection fraction 
HFmrEF- Heart failure with mid-range ejection fraction 
LVSD- Left Ventricular systolic Dysfunction 
ESC- European Society of Cardiology 
ACEI- Angiotensin-converting enzyme inhibitor 
ARB- Angiotensin receptor blocker 
MRA- Mineralocorticoid receptor antagonist 
ARNI- Angiotensin receptor-Neprilysin inhibitor 
CCB- Calcium-channel blocker 
JVP- Jugular venous pressure 
MI- Myocardial infarction 
HR- Heart rate 
 
 
 
 
  
Table of Contents 
ABSTRACT ........................................................................................................................................... 5 
SAŽETAK .............................................................................................................................................. 6 
INTRODUCTION ................................................................................................................................. 1 
HF TERMINOLOGY ............................................................................................................................ 1 
EPIDEMIOLOGY AND ETIOLOGY OF HF ..................................................................................... 2 
PHARMACOLOGICAL TREATMENT OF HEART FAILURE ..................................................... 3 
HF IN CROATIA .................................................................................................................................. 6 
HF IN THE UK ..................................................................................................................................... 8 
AIM OF THE STUDY ........................................................................................................................10 
METHODS ..........................................................................................................................................10 
RESULTS .............................................................................................................................................11 
ETIOLOGY ....................................................................................................................................................... 11 
DIAGNOSIS ..................................................................................................................................................... 12 
TREATMENT ON DISCHARGE FOR HF ...................................................................................................... 12 
ACEI AND ARB ............................................................................................................................................. 13 
SACUBITRIL/VALSARTAN ............................................................................................................................. 14 
BETA-BLOCKERS ........................................................................................................................................... 14 
MRA ................................................................................................................................................................ 14 
DIURETICS ...................................................................................................................................................... 15 
DIGOXIN ......................................................................................................................................................... 15 
IVABRADINE ................................................................................................................................................... 15 
MONITORING ....................................................................................................................................15 
DISCUSSION.......................................................................................................................................16 
LIMITATIONS ...................................................................................................................................19 
CONCLUSION .....................................................................................................................................19 
ACKNOWLEDGMENT .....................................................................................................................20 
REFERENCES: ....................................................................................................................................21 
BIOGRAPHY ......................................................................................................................................24 
 
 
 
 Abstract  
 
Optimal medical treatment for heart failure with reduced ejection fraction 
Author: Mohammad Tareq Rahimy 
 
This study assessed the optimal medical therapy for HFrEF among patients in 
the outpatient clinic of University Hospital Centre Zagreb during the last year and 
compared the results with a study done by the Croatian HF registry in 2011. I 
measured improvements in the therapy and compared the results with similar studies 
performed in the UK.  
Patients attending outpatient clinic on Wednesdays at Clinical Hospital Centre 
Zagreb for the past year were audited. The data collected included clinical features of 
HF, medications and the doses of medication prescribed which were then compared 
with the current ESC guidelines. In total, 108 patients were included in the study. Of 
which, 83 were men (76%) and 25 women (24%). Predominant HF etiology included, 
dilated cardiomyopathy (49%), ischemic cardiomyopathy (33%) and hypertensive 
cardiomyopathy (5%). All patients had reduced left ventricular EF and were on HF 
medication.  Ninety-five percent of the patients received beta-blockers (compared 
with 58% in 2011), 53% were on an ACEI or an ARB (compared with 60% in 2011), 
87% received a MRA (compared with 44% in 2011) and 89% were on diuretics 
(compared with 86% in 2011).  Digoxin was given to only 7.5% (compared with 30% 
in 2011) and ivabradine was used by 3 patients (2.8%). Although this study 
demonstrated that there is an increase in prescribed doses of HF optimal medication, 
the mean daily dose of most medical therapy is still significantly below the maximum 
tolerated evidence-based doses as recommended by the ESC guidelines of 2016. 
Keywords: Heart failure with reduced ejection fraction, left ventricular systolic 
dysfunction, heart failure management, ACE inhibitor, mineralocorticoid receptor 
antagonist, beta-blocker, angiotensin receptor-neprilysin inhibitor. 
  
Sažetak 
 
OPTIMALNA MEDIKAMENTNA TERAPIJA U BOLESNIKA S 
REDUCIRANOM SISTOLICKOM FUNKČIJOM. 
Autor :  Mohammad Tareq Rahimy 
 
U ovom diplomskom radu ispitao sam učestalost propisivanja optimalne 
medikamentne  terapije u bolesnika s popuštanjem srca s reduciranom istisnom 
frakcijom (HFrEF, engl. heart failure with reduced ejection fraction) i usporedio 
dobivene rezultate sa izvješćem Hrvatskog registra bolesnika sa zatajivanjem srca iz 
2011. godine. Mjerio sam poboljšanja u terapiji i usporedio dobivene rezultate sa 
sličnim studijama provedenim u Velikoj Britaniji.  
U ispitivanje su uključeni bolesnici koji su posjetili Ambulantu za zatajivanje 
srca srijedom u Kliničkom bolničkom centru Zagreb tijekom protekle godine. 
Prikupljeni podaci uključili su kliničke značajke HFrEF-a, vrste i propisane doze 
lijekova koji su zatim uspoređeni s važećim smjernicama Europskog kardiološkog 
društva. Ukupno je uključeno 108 bolesnika, od čega 83 muškarca (76%) i 25 žena 
(24%). Glavni uzroci HFrEF-a bili su dilatacijska kardiomiopatija (49%), ishemijska 
kardiomiopatija (33%) i hipertenzivna kardiomiopatija (5%). Svi bolesnici imali su 
disfunkciju LV s reduciranom EF i liječeni su lijekovima za srčano popuštanje. 
Devedeset pet posto bolesnika primalo je beta-blokatore (u usporedbi s 58% u 2011.), 
53% je uzimalo ACEI ili ARB (u usporedbi s 60% u 2011.), 87% je liječeno MRA (u 
usporedbi s 44% u 2011.) i 89% je bilo na diureticima (u usporedbi s 86% u 2011). 
Digoksin je propisan samo u 7,5% (u usporedbi s 30% u 2011.), dok je ivabradin 
propisan samo u 2,8%.  
Ovo istraživanje je pokazalo da usprkos porastu učestalosti propisivanja 
lijekova za optimalno liječenje bolesnika s HFrEF, srednja dnevna doza lijekova u 
većine bolesnika i dalje je znatno ispod maksimalnih doza kakve su preporučene u 
posljednjim Smjernicama ESC za liječenje bolesnika sa zatajivanjem srca iz 2016. 
godine. 
Ključne riječi: Optimalno liječenje bolesnika s HFrEF, disfunkciju LV s reduciranom 
EF, ACEI, ARB.  
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Introduction 
 
Heart failure is complex and common clinical syndrome that can result from 
any structural and functional cardiac impairment in which either the ability of 
ventricular filling or ejection of blood form the ventricle is compromised. HF may be 
caused by an array of different disorders of the myocardium, pericardium, 
endocardium, heart valves and vessels and certain metabolic disorders. Most HF 
patients however, have symptoms due to left ventricle myocardial dysfunction. LV 
dysfunction is categorized into HF with reduced ejection fraction (HFrEF) diagnosed 
when LVEF <40 % (also known as systolic HF), and HF with preserved ejection 
fraction (HFpEF) typically considered as LVEF50 % (known as diastolic HF). In the 
last ESC guidelines from 2016 a new term was introduced which covers patients with 
HF with a LVEF that ranges from 40% to 49% termed as heart failure with mid-range 
ejection fraction (HFmrEF). 
Dyspnea, fatigue and fluid retention are the most typical manifestation of a 
patient presenting with HF that may be accompanied by signs such as elevated JVP 
and pulmonary crackles. Dyspnea and fatigue may limit exercise tolerance, whereas 
fluid retention may lead to pulmonary and/or splanchnic congestion and peripheral 
edema. After the diagnosis, it is central to demonstrate an underlying cardiac cause of 
HF such as abnormalities in the myocardium. This is crucial for therapeutic reasons, 
as the exact pathology determines the choice of treatment used (1)(2). 
HF Terminology 
 
The current definition and terminology used in patients with HF is restricted to 
phases at which clinical symptoms become apparent. However, before any clinical 
symptoms become apparent, asymptomatic patients already have structural and 
functional systolic or diastolic LV abnormalities, which are precursors to 
symptomatic HF with poor outcomes. It is therefore important to note that 
recognizing patients at the asymptomatic precursor stage may reduce mortality(1).  
 2 
Historically HF has been classified based on the location of the failure such as 
left ventricular, right ventricular or biventricular or based on time of onset e.g. acute 
or chronic HF. Clinically, the main terminology used to describe HF is based on 
LVEF usually measured using echocardiography.  Normal LVEF is typically 
considered to be greater than ≥50% also known as HF with preserved EF (HFpEF).  
Patients with reduced LVEF are those with <40% (HFrEF). LVEF in the range of 40-
49% is now defined as mid-range or HFmrEF. It is important to differentiate patient 
with HF based on LVEF as it will narrow down the etiology, demographics, 
comorbidities and response to therapy (3) 
Epidemiology and etiology of HF 
 
The prevalence of HF is relatively high, though it depends of the definition 
applied. In the developed countries it is estimated that approximately 1-2% of the 
adult population suffer from symptoms of HF. This number is known to rise to ≥10% 
among people  >70 years of age (4).  According to the Rotterdam study from 2004, 
the lifetime risk of HF at age 55 years is estimated to be 33% for men and 28% for 
women (5). 
The epidemiological and etiological profiles between HFpEF and HFrEF are 
shown to be different. Patients with HFpEF are usually older women and more 
commonly have a history of high blood pressure and atrial fibrillation (AF), while 
myocardial infarction (MI) most commonly precede HFrEF. The features of patients 
with HFmrEF are not yet clearly known and therefore future studies should aim to 
characterize these populations (6). 
Concerning the etiology of HF; these vary among world regions. Additionally 
there is much overlap between several pathologies whether it may be cardiovascular 
or non cardiovascular that connive to cause HF. Consequently to this, there is no 
agreed single classification for the cause of HF (2). Thus, the diagnostic work up 
should include identifying these diverse pathologies to apply the best possible 
therapeutic intervention.   
The etiologies of HF could be due a diseased myocardium such as ischemic 
heart disease, toxic damage, infiltration, metabolic derangements and genetic 
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abnormalities. Ischemic heart disease and genetic abnormalities in HCM, DCM and 
restrictive cardiomyopathy may be more commonly seen. 
Another cause of HF may be due to abnormal loading. Conditions such as 
hypertension, valve and myocardium structural defects, high output states, volume 
overload. Pericardial and endomyocardial pathologies are also known etiologies of 
HF. Furthermore; tachyarrhythmias are also associated with HF (4)(5)(6). 
Pharmacological treatment of Heart failure 
 
Evidence-based medicine suggests that onset of symptomatic HF may be 
delayed or even prevented if timely interventions are carried out to treat 
asymptomatic LV systolic dysfunction and controlling other modifying risk factors. 
Many clinical trials have shown that controlling hypertension will delay onset of HF 
and may even prolong life (7)(8)(9). Therefore many antihypertensive medications 
have shown to be very effective in treating HF both in patients with and without a 
history of MI (7)(8) 
The goal of pharmacological intervention in HF is to improve patient’s quality 
of life by preventing hospitalization, improve functional capacity and clinical status 
and ultimately to reduce mortality.  
Guideline-directed medical therapy for HFrEF includes four drug classes that 
reduce mortality. Angiotensin-converting enzyme inhibitor (ACEI), angiotensin-
receptor blockers (ARB), mineralocorticoid receptor antagonist (MRA) and beta-
blockers have all shown to improve survival in patients with HFrEF and are 
recommended for use in all these patients unless contradicted or not tolerated. But 
even with maximal therapy with these drugs, symptoms may persist and mortality 
remains high(2).  
A novel drug therapy known as LCZ696 has been found to lower mortality in 
theses patients. Angiotensin Receptor Neprilysin Inhibition (ARNI) versus ACEI 
(enalapril) was investigated in the recently completed PARADIGM-HF trial (10). 
Treatment with LCZ696 for a median of 27 months resulted in relative reduction of 
20% in death from cardiovascular causes and hospitalization. The trial also showed an 
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overall mortality reduction of 16% compared to enalapril(11).  This compound that 
combines an ARB (valsartan) and a neprilysin inhibitor (sacubitril) is therefore 
recommended by the ESC-guidelines to replace ACEIs in HFrEF patients who are 
still symptomatic despite optimal pharmacological treatment. 
A symptomatic HFrEF patient should initially be put on a combination of 
ACEI and a Beta-Blocker and followed up. If the patients remain symptomatic, MRA 
should be added and titrated up to maximum tolerated evidence-based dose. Upon 
review if still symptomatic with LVEF<35%, ACEI should be replaced with 
angiotensin receptor neprilysin inhibitor (ARNI) in patients who are able to tolerate 
ACEI and/or ARB(2).  
MRAs are drugs that block receptors that bind aldosterone and other steroid 
hormones. ESC guidelines recommend the use of spironolactone or eplerenone in all 
symptomatic patients with HFrEF and LVEF of 35% or less in spite of treatment with 
ACEI and a beta-Blocker, which is associated with a reduction in mortality from 
cardiovascular causes or hospitalization from HF (2)(12)(13). MRAs should be used 
cautiously in patients with impaired renal function and in those with serum potassium 
levels >5.0 mmol/L. Therefore, regular renal function tests and serum potassium 
levels should be performed in regular intervals according to local clinical guidelines. 
Guidelines also recommend the use of ivabradine, which is shown to improve 
outcome by reducing elevated heart rate, which is often seen in HFrEF.  Ivabradine 
inhibits the If  channel in the sinus node and should therefore only be used for patients 
with sinus rhythm. The European Medicine Agency (EMA) approved ivabradin for 
use in patients with HFrEF in sinus rhythm with a resting HR of 75 bpm or above. In 
this group of patients ivabradine showed a survival benefit according to SHIFT study 
analysis performed in 2013 by Bohm M et al. (14) However, if the patient has sinus 
rhythm with QRS duration of  > 130 msec then the need for CRT should be evaluated 
(14). 
If after careful use of the above-mentioned optimal therapy, the patient still 
has resistant symptoms, then the use of left ventricular assist device (LVAD) or heart 
transplantation should be considered (2). 
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Diuretics should be used in conjunction with above-mentioned medications in 
patients with signs of congestion (2). Even though the effects of diuretics on mortality 
and morbidity is not fully investigated, a Cochrane meta-analysis from 2012 
conducted by Faris R et al. (15) concluded that conventional diuretics have shown to 
reduce the risk of death and worsening of HF compared with placebo. Furthermore, it 
also appeared to improve exercise tolerability compared to active control.  
An important point that needs mentioning is that the recommended drugs 
should be up titrated to the maximum tolerated evidence-based dose to achieve full 
therapeutic effects. A good example of which is ACEIs. In a study of Pan-European 
registry from 2013, Maggioni AP et al. (12) reported that majority of HF patients 
receive suboptimal doses of ACEI and thus suggested that the current guidelines 
regarding dosages of HF medication should be seriously considered in daily clinical 
practice.  
Furthermore, it is also important to mention drugs that are not recommended 
and believed to cause harm in symptomatic patients with HFrEF. These drugs consist 
of calcium-channel blockers (CCBs). Non-dihydropyridine CCB such as diltiazem 
was shown to cause more cardiac events in patients with left ventricular dysfunction 
compared to the placebo group in The Multicentar Diltiazem Postinfarction Trial 
(MDPIT) (16). Among the dihydropyridine CCBs, only amlodipine and felodipine 
have shown to have positive safety profiles in patients with HFrEF, but should only 
be used if there is considerable indication for use for such drugs in patients with HF 
(17)(18).  
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According to the data above, the proportion of patients receiving optimal 
medical therapy in 2014 decreased for diuretics and MRAs.  The use of beta-blockers 
increased slightly in comparison with 2011 but the use of ARBs increased by almost 
3-fold, while the use of ACEI remained stable (19)(20). 
Daily doses for ACEI prescribed in 2011 were:  lisinopril (9 mg), ramipril (3.5 
mg), trandolapril (1.8 mg), fosinopril (9 mg), cilazapril (3 mg), enalapril (6.8 mg), 
perindopril (3.4 mg) and captopril (100 mg). Mean daily dose of beta-blockers was 
calculated to be 2.8 mg for bisoprolol and 26.1 mg for carvedilol (19). 
 
 
Table 1. Mean daily dose of HF medication in 2011 versus recommended target dose. 
 Mean Daily Dose 
Given in 2011 (mg) 
Recommended Target Dose according 
to ESC guideline (mg) 
ACE-I     
Captopril 100 150 
Enalapril 6.8 20-40 
Lisinopril 9 20-35 
Ramipril 3.5 10 
Trandolapril 1.8 4 
   
Beta-Blockers     
Bisoprolol 2.8 10 
Carvedilol 26.1 50 
Nebivolol  10 
 
Both ACEI and beta-blockers mean daily doses given in 2011 were 
significantly below the maximum tolerated evidence-based doses to achieve maximal 
therapeutic effect. We hope to see an improvement on this data in this study. 
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The comparison of two audits show that the rate of compliance of the 
physicians to adhere to both national and international guidelines when treating 
chronic HF generally increased from 2011 to 2014. Not only, there was an 
improvement seen on the rates of prescription for evidence-based pharmacotherapies 
but also clear improvement in prescribing maximum tolerated dose and monitoring of 
HF patients (23). 
 Another point of priority in this audit was education of HF patients about 
exercise and cardiac rehabilitation. The authors noted that although the number of 
patients who were educated about the benefits of regular exercise increased from 36% 
in 2011 to 100% in 2014, the actual number of patients that were referred to a HF 
rehab program or enrolled in HF rehab program still remained very low. The reason 
behind could be due to inadequate levels of patient participation either due to 
financial restrictions or lack of rehabilitation services geographically within reach and 
for the comorbid and elderly patient, lack of home-based alternative (23). 
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Aim of the Study  
 
The primary objective of this pilot study was to see: 
1) If the ESC guideline regarding the optimal medical therapy of HFrEF is being 
adhered in daily clinical practice and to what percentage are they adhered to? 
2) To compare the results with the results published in 2011 (18) by Croatian HF 
registry and one in 2014 by Croatian Cardiac Society regarding treatment of HF in 
Croatia (19) and to observe the changes and improvements.  
3) To compare the result with similar study performed in the UK and to contrast the 
use of optimal medical therapy in HFrEF between Croatia and the UK.  
 
 
Methods  
 
In this retrospective study, the data was collected from the Electronic Data 
Base at the University Hospital Center Zagreb. The study population included patients 
who visited the HF outpatient clinic. I obtained the data from only the patients who 
visited the clinic on a Wednesday and had EF< 40%.  Furthermore, full medical 
treatment they were receiving and the clinical feature of HF were noted which I then 
used to conclude and discuss my results. 
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Table 2.  Table comparing mean daily dose of HF medication in 2018 with 2011 and 
recommended target dose according to ESC guidelines. 
 
ACEI and ARB 
 
Forty-four percent of patients were discharged on an ACEI, and 53% of the 
patients received either and ACEI or an ARB on discharge. There is a slight decrease 
in number of patients receiving ACEIs compared with the data from the Croatian HF 
registry from 2011  and 2014 (20). This may be due to introduction of the new 
combination drug - sacubitril/valsartan.  The mean daily dose on discharge was 4.2  
mg for ACEIs and 158 mg for ARBs. Although there is a slight increase in the mean 
daily dose of ramipril (4 mg versus 3.5 mg in 2011), the evidence-based dose of this 
disease-modifying drug according to the ESC guidelines should be 10 mg once daily. 
 Mean Daily 
Dose Given 
2011(mg) 
Mean Daily 
Dose Given 
2018 (mg) 
Recommended Target 
Dose according to ESC 
guidelines (mg) 
ACE-I    
Ramipril 3.5 4 10 
ARBs    
Valsartan - 158 320 
Beta-Blockers    
Bisoprolol 2.8 5.2 10 
Carvedilol 26.1 32 50 
Nebivolol - 5.8 10 
ARNI    
Sacubitril/Valsartan - 236.4 400 
MRA    
Spironolactone/ 
Eplerenone 
- 34.2 50 
Diuretics    
Furosemid - 93 40-240 
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Sacubitril/Valsartan  
 
This new therapeutic class of drug was first introduced in the ESC guidelines 
from 2016 after a trial found this drug to be superior to ACEI in reducing 
hospitalization for worsening HF and cardiovascular mortality (2). Fourty-one percent 
of patients in this study were prescribed sacubitril/valsartan on discharge with a mean 
daily dose of 236 mg. However, for the majority of patients on this medication, during 
their last consultation, an increase in the dose was advised.  The recommended daily 
dose according to ESC guidelines is 400 mg daily. 
 
Beta-Blockers 
 
Ninety-five percent of the patients in this study were discharged with a beta-
blocker. This is significantly higher than 61% recorded in 2014 and 58.3% recorded 
in 2011. The guidelines recommend the use of beta-blockers and ACEI s as soon as 
the diagnosis of HFrEF is established as the two drugs acts complementary and 
reduces mortality and morbidity. The mean daily dose for beta-blockers has also 
increased. Bisoprolol was prescribed with a mean daily dose of 5.2mg compared to 
2.8mg in 2011(18). Carvedilol daily dose increased from 26.1mg in 2011(18) to 32mg 
now.  
 
MRA 
 
Eighty-seven percent of the patients were prescribed MRAs on discharge. This 
is considerably higher than the 31% recorded in 2014(19) and 44.2% in 2011(18). The 
mean daily dose given was 34.2mg. Men were more likely to be prescribed 
eplerenone compared to women (44% men versus 30% women). The opposite was 
true for spironolactone (56% men versus 70% women). MRAs are only prescribed 
when the patients still remain symptomatic despite the use of beta-blockers and ACEI 
and/or have EF< 35%. 
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Diuretics 
 
Eighty-nine percent of the patients in the study were discharged on diuretics. 
This is slightly higher than the previously recorded data in 2014(19) and 2011(18). 
Usual daily doses of loop diuretics in patients with heart failure ranges from 40-
240mg. In our study the mean daily dose was 93mg . 
 
Digoxin 
 
Only 7.5% received digoxin compared to 30% of patients in 2011. That is in 
concordance with the recommendation from the latest ESC Guidelines on HF. 
 
Ivabradine  
 
This novel sino-atrial node inhibitor which is advocated as a treatment option 
for controlling heart rate in certain HF population was only used in 2.8% of patients. 
This could be explained by significant participation of the patient in the costs of this 
drug in Croatia. 
Monitoring  
 
All patients with chronic HF require regular monitoring. When examining the 
patients, clinical assessment of functional capacity, fluid status, cardiac rhythm and 
nutritional status of the patient should be done. Supplementary tests should look into 
serum urea, electrolytes, creatinine and eGFR. However, more importantly a review 
of medication must be done and the need for an increase in dose or changes due to 
possible side effects should be considered. If patients present with significant 
comorbidity or if their condition has deteriorated, more detailed monitoring should be 
pursued. The clinical status and stability of the patients will depict the frequency of 
monitoring, however, the ESC guidelines recommend a 6-monthly review of the 
patient unless the clinical condition or medication have changed. All the patients in 
this study were stable and were suggested for review in 6-9 months.  
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Discussion 
 
According to the definition of an epidemic, heart failure can indeed be 
considered an epidemic of present day. Cardiovascular diseases are the leading cause 
of morbidity, mortality and hospitalization in Croatia. HF alone contributes to 
significant morbidity and mortality and is the 7
th
 most common cause of death in 
Croatia (19). Although HF still has a high five-year mortality rate with tendency to 
increase with increasing age, in the last 15 years, Croatia has seen a 60% decrease in 
HF-related mortality. This trend can be attributed due to early diagnosis, improved 
treatment modalities and medications for HF and other cardiovascular diseases (20). 
The chronic care of patients with HF should be embedded within a multidisciplinary 
program. Both national and international guidelines advice on implementation of such 
programs to reduce mortality and morbidity within HF population. Guidelines place 
emphasis on lifestyle advice, usage of pharmacological evidence-based medications, 
monitoring at appropriate interval, education of the patient regarding the therapies and 
rehabilitation.  
 This study focused on the use of optimal medical therapy for patients with 
HFrEF. When comparing the results of the study with the results from previous study 
performed in 2011, the prescription for guideline recommended evidence-based 
optimal therapy for HFrEF significantly improved in the last 7 years. The rate of 
compliance of the physicians to adhere to optimal medical therapy is more in 
concordance with the guidelines now than in 2011.  
This study documents an increase of close to 40% in prescribing beta-blockers to HF 
patients (95% versus 58% in 2011). This is 4% more than prescription rates for beta-
blocker for HF patients in the UK in 2014, which showed a rate of 91% (previously 
77% in 2011). There is also an increase in mean daily dose of beta-blockers 
prescribed to HF patients. Both bisoprolol (5.2 mg compared to 2.8 in 2011) and 
carvedilol (32 mg compared to 26.1 mg) doses increased, however the recommended 
target doses for these medications are much higher than the doses prescribed.  
The use of MRAs in HF almost doubled since 2011 (87% versus 44.2% in 2011).  
According to the ESC guidelines, MRAs should be used in all symptomatic HFrEF 
patients with LVEF of 35% or less in spite of treatment with ACEI and a beta-
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blocker. This is shown to reduce mortality and hospitalization from HF (2)(12)(13). 
Spironolactone is associated with dose-dependent sexual side effects and 
gynecomastia and therefore male patients may not always be willing to use this, 
however, eplerenone on other hand has a small charge associated with each 
prescription, which may be a financial burden for the patient. In this study, men were 
more likely to be prescribed eplerenone than spironolactone and the opposite was true 
for women. MRA usage in the UK increased from 44% in 2011 to 56% in 2014, 
which is significantly less than the current rates in Croatia. 
ESC guidelines recommend the use lowest achievable dose of diuretics to maintain 
euvolemia in patients with HFrEF. Diuretics use also increased slightly since 2011 
(88.8% versus 86.3% in 2011). The mean daily dose of furosemid (93 mg) is within 
the range (40-240 mg) recommended by ESC guidelines. Both UK and Croatia show 
similar rates of diuretics use in HF with an uptrend since 2011. 
The use ACEIs has been showing a downtrend since 2011. Only 44% of the patients 
received ACEI compared to 48% in 2014 and 53% in 2011. Fifty-three percent of the 
patients received either an ACEI or an ARB on discharge.  The downtrend is probably 
due to the introduction of a new therapy - sacubitril/valsartan in the ESC guidelines of 
2016. In the PARADIGM-HF trial (10) the use of this therapy showed superiority 
over ACEI in patients with symptomatic HFrEF with LVEF ≤40% and elevated 
plasma NT-proBNP ≥600 pg/mL or patients who had been hospitalized for HF within 
the last 12 months. This population of the patients received sacubitril/valsartan (400 
mg daily) that showed reduced mortality, morbidity and hospitalization rate for 
worsening HF. ESC guidelines therefore recommends the use of this therapy in 
patients who fit this profile (2). Forty-one percent of patients in this study received 
this therapy with mean daily dose of 236.4 mg.  
 There are certain areas of implementation in HF patients that need to be 
addressed. These include: firstly the use of optimal medical therapy, which was the 
main goal of this study, secondly follow-up and monitoring of HF patients, which are 
again clearly set in the guidelines and thirdly patient education and finally cardiac 
rehabilitation. The latter is an established part of the therapeutic intervention package 
in areas of cardiology such as post-MI and following a CABG procedure but despite 
being recommended and proven to have clear benefits for HF patients, it has been 
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relatively neglected within HF (23). In the audit of 2014 in the UK, the number of HF 
patients that were told about the benefits of regular cardiovascular exercise reached 
almost 100%, however, the number of patients that were referred or enrolled into a 
HF rehab program totaled less than 10% (23). Data throughout Europe shows similar 
findings and this can be attributed to geographical variations and lack of finances. 
Hence, the focus of the multidisciplinary team in charge of HF patients should be 
directed towards expanding and investment into rehabilitation services for HF 
patients. 
Patient education at discharge is found to be vital to improved outcomes of HF. 
Education of patients or family members of HF patients and stressing the importance 
of medication adherence, sodium and fluid restriction and recognition of signs and 
symptoms of worsening HF early, are shown to reduce re-hospitalization rates of HF 
patients (24). Some estimates put the preventable readmission rates for HF patients at 
54% and attributes lack of compliance with medication, lack of sodium and fluid 
restriction and failure of follow-up as the primary culprit for the high rate of re-
hospitalization (25). Overall, patients who have not been educated about their disease 
and their medication are at a disadvantage. The management of a HF patient requires 
a multidisciplinary team, and cardiac nurses also play a fundamental role.  
I believe the future lies in training cardiac nurse to take on primary practitioners role 
in educating and evaluating patients self-care abilities. These nurses can be trained to 
take on the role of educators and educate patients about their medication and diet and 
also how to adjust medication doses according to patient’s fluid status and BP without 
coming to the hospital. For all this to happen a discharge management program needs 
to be instituted with evidence-based guidelines, where cardiac nurses take on the lead 
in educating patients and thus improving the level of care for HF patients. 
 
 
 
 
 19 
Limitations 
 
The study focused only on ambulatory patients of HF in the outpatient’s clinic, 
which understandably does not represent the whole population, however, the data was 
randomly collected to avoid bias and to represent the population within this centre. Of 
course, since the data was collected from a single centre, it makes it subject to 
selection bias and thus not entirely generalizable to whole Croatia, yet the results 
displayed a general trend seen in previous studies on this topic.  Furthermore, the 
results were directly compared with ESC guidelines without taking clinical 
monitoring of the patients into account. Further studies should take all the above-
mentioned points into account by collecting the data nationwide to avoid selection 
bias.  
 
 
Conclusion  
 
 
This study demonstrated a significant improvement in optimal medical therapy 
for HF and an increased adherence of the physicians to the ESC guidelines. However, 
the target daily dose for most medication is still insufficient and remains below the 
recommended dose. An improvement in this area would certainly help in care of HF 
patients. In diagnosing HF, the use of NT-proBNP still remains very low. The 
multidisciplinary team in charge of HF patients must always strive to provide the best 
possible care for the patients. General physicians, internists and cardiologists should 
always aim to adhere to the guidelines and improve management of their patients by 
simple education of their patients about HF and its treatment, whereas, cardiac nurses 
should be encouraged to individualize discharge management and help with cardiac 
rehabilitation programs. 
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